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Recurrence of FSGS occurs in 30–40% of allografts. Therapies for recurrence are not well established. We retrieved all published
reports depicting kidney transplant recipients with focal segmental glomerulosclerosis (FSGS) recurrence, treated with rituximab,
to determine factors associated with treatment response. We found 18 reports of 39 transplant recipients who received rituximab.
By univariate analysis for two outcomes (no response versus any response), fewer rituximab infusions and normal serum albumin
atrecurrencewereassociatedwithtreatmentresponse.For3outcomes(noresponse,partialandcompleteremission),malegender,
fewer rituximab infusions, shorter time to rituximab treatment, and normal serum albumin were associated with remission.
Multivariate analysis for both models revealed that normal serum albumin at FSGS recurrence and lower age at transplant were
associated with response. Rituximab for recurrence of FSGS may be beneﬁcial for only some patients. A younger age at transplant
and normal serum albumin level at recurrence diagnosis may predict response.
1.Introduction
Focal segmental glomerulosclerosis (FSGS) is a common
cause of idiopathic nephrotic syndrome in childhood and
comprises over one-third of such cases in adults. Patients
withFSGSareatasubstantialriskofprogressingtoend-stage
renal disease (ESRD) requiring dialysis or renal transplant
[1].
Following transplantation, 30 to 40% of patients with
FSGS, due to a presumed underlying immune defect, will
have recurrence of FSGS [2] which negatively impacts
allograft survival. In contrast, FSGS secondary to mutations
in genes encoding proteins expressed in the podocyte and
elsewhereintheglomerularcapillarywallhasalowincidence
of recurrence [3].
The underlying immune disorder leading to FSGS
is not known, but is probably multifactorial. It has
been hypothesized that FSGS is caused by a circulating
glomerular permeability factor released by T cells [4].
Hence, plasmapheresis is the most commonly used therapy
for established FSGS recurrence, but it is not always eﬀective
[5]. In the published literature, 70% of children and 63% of
adults will have some response to plasmapheresis, especially
if started early after diagnosis and repeated frequently [5].
Other investigators have proposed that B cells may be
involved in the pathogenesis of FSGS through an abnormal
cross-talkwithTcellsorbydirectlyreleasingthestilluniden-
tiﬁed permeability factor [6, 7]. Benz et al. treated with
rituximab a patient with idiopathic thrombocytopenic pur-
pura who also had steroid-dependent nephrotic syndrome
[8]. After rituximab, the patient was able to discontinue
oral corticosteroids without relapsing. Nozu et al. reported
on a young boy with recurrence of FSGS in his allograft
that developed posttransplant lymphoproliferative disorder
(PTLD) [9]. After treatment that included rituximab, the
PTLD resolved and the proteinuria abated. Other case
reports and case series throughout the following years have
documented both successes and failures in the treatment2 Journal of Transplantation
of recurrent FSGS with rituximab [9–26]. There are no
prospective studies evaluating the eﬀectiveness of rituximab
in posttransplant FSGS. Yet, clinicians need better data for
improved clinical decision making since rituximab use is not
benignandmaybeassociatedwithsigniﬁcantcomplications.
The purpose of this study was to analyze all the existing
reports and to determine if we can identify which factors are
associated with remission of the clinical recurrence following
rituximab treatment in posttransplant FSGS, thereby allow-
ing for more focused therapy.
2.MaterialsandMethods
We retrieved reports of rituximab use in recurrent FSGS
from PubMed using the search terms “nephrotic syndrome,
treatment, and rituximab”. Our initial search yielded 96
articles. We then excluded review articles, reports of rit-
uximab use in native kidney disease or in other disease
recurrence after transplant. Only articles written in English
were included. Our ﬁnal study group included 18 reports
describing 36 unique patients, plus 3 unpublished patients
at our own center. One retrospective questionnaire study
to members of the International Pediatric Nephrology
Association that described 15 patients with recurrent FSGS
was not included since some of the patients may already
have been reported as case reports/series [27]. Data were
extracted from each of these reports using a standardized
questionnaire. The authors were individually contacted in
order to obtain the following variables that were not always
reported: recipient age at diagnosis and transplant, recipient
gender, recipient race, donor age, donor gender, donor
race, transplant source, time from transplant to recurrence,
serum albumin level at recurrence, proteinuria at recurrence,
number of plasmapheresis sessions, pretransplant plasma-
pheresis, immunosuppression used, presence of an acute
rejection prior to or after the diagnosis of relapse, number
of rituximab doses, time from transplant and relapse to
rituximab administration, and the presence of PTLD.
We deﬁned clinical recurrence by the presence of
nephrotic range proteinuria, since this was reported as
present in all study reports and was the basis for treatment
initiation. Not all cases had hypoalbuminemia or edema
at the time of recurrence of FSGS. All but 5 patients
underwent renal biopsies for diagnostic purposes. However,
all patients had heavy proteinuria and were considered to
have recurrence of FSGS. Complete response to therapy was
deﬁned as absence of proteinuria (protein/creatinine ratio
of <0.3). Partial response to therapy was deﬁned as more
than 50% decline in proteinuria to a protein/creatinine level
between 0.3 and 2. No response to therapy was deﬁned when
proteinuria failed to improve by at least 50% or remained
above a protein/creatinine level above 2.
Given the small number of reports in the study sample
and uncertainty of distribution of these continuous variables
in the population at large, we chose to analyze all continuous
variables by the more rigorous Kruskal-Wallis nonparamet-
ric test. Continuous data are expressed as median and range.
Categorical variables were analyzed by the Chi-square test of
Table 1: Demographic characteristics of renal transplant patients
with recurrence FSGS that received rituximab. Values expressed as
median (range) or proportion (%).
Variable Results
Age at diagnosis (years) 6 (1–40)
Age at transplant (years) 18 (5–48)
Time to end stage renal disease (years) 3 (0.16–19)
Recipient male 22/39 (56.4)
Deceased donor transplant 26/39 (66.7)
Time to relapse of FSGS (days) 3 (1–3513)
Serum albumin at relapse (g/dL) 2.5 (1.2–4.4)
Proteinuria at relapse (g/day) 6.2 (1.1–97.4)
Diagnosis of PTLD 3/39 (7.7)
Number of plasmapheresis treatments 21 (0–133)
Number of rituximab doses 4 (1–6)
Complete response to therapy 17/39 (43.5)
Time to response from rituximab (months) 2 (0.63–12)
Fisherexacttest,asappropriate,andareexpressedaspropor-
tion (%). We handled response to therapy in two diﬀerent
ways: either as a two outcome variable (no response/any
response) or three outcome variable (no response/partial
response/completeresponse).Thenumberofplasmapheresis
sessions was entered into separate multivariate models either
asacontinuousvariableorasadiscreteorderedvariable(<20
sessions, 20–50 sessions, >50 sessions).
Variables that showed a P value of <0.10 by univari-
ate analysis were entered into stepwise backward logistic
regression multivariate models to assess for association with
clinical response. All statistical analyses were carried out
using SAS 9.2 (Cary, NC, USA). A P value of <0.05 was
considered as signiﬁcant.
3. Results
The full cohort comprised 39 renal transplant patients
from 18 published reports and our center’s unpublished
experience. The demographic characteristics for the patients
are provided in Table 1. The individual contacting of cor-
responding authors helped us obtain complete data in all
39 subjects for most of the variables. The median age
of the patients at the time of transplant was 18 years
(range 5–48 years). Nineteen of the 39 patients were in the
pediatric age group at the time of transplant. A negative
genetic mutation for podocin was documented in 4 patients
diagnosed with nephrotic syndrome at a young age and
was not reported for the remaining patients. All but one
patient were receiving maintenance immunosuppression
with oral corticosteroids plus a combination of either
tacrolimus/MMF or cyclosporine A/MMF.
The clinical recurrence occurred early, with 61.5% of
them presenting within the ﬁrst week and 74.3% within
the ﬁrst month after transplant. Recurrence beyond one
year of transplant occurred in only 10.2% of the cohort,
in one case developing almost 10 years later. PosttransplantJournal of Transplantation 3
Table 2: Univariate analysis for the 2-outcome model of any response versus no response to rituximab therapy. Values expressed as median
( r a n g e )o rp r o p o r t i o n( % ) .
Variable Any response
(n = 25)
No response
(n = 14)
P value
Age at diagnosis (years) 5 (1–33) 12 (1.9–40) 0.07
Age at transplant (years) 16 (5–48) 30 (5.5–48) 0.09
Male gender 16/25 (64) 6/14 (42.8) 0.31
Time to end stage renal disease (years) 3 (0.16–19) 4 (0.5–12) 0.42
Time to relapse (days) 2 (1–3513) 22 (1–828) 0.13
Deceased donor source 16/25 (64) 10/14 (71.4) 0.73
Serum albumin at relapse 3.25 (1.4–4.4) 2.3 (1.2–3.3) 0.02
Proteinuria at relapse (g/day) 8 (1.1–97.4) 7.64 (2.4–20) 0.98
Plasmapheresis 21 (0–100) 27 (9–133) 0.36
Pretransplant plasmapheresis 7/25 (28) 2/14 (14.4) 0.45
Posttransplant plasmapheresis 24/25 (96) 14/14 (100) 1.00
Rituximab doses 3 (1–6) 4 (2–6) 0.007
Time from transplant to rituximab (days) 150 (4–3543) 276 (65–1050) 0.29
Time from relapse to rituximab (days) 136 (3–1086) 179 (57–1048) 0.32
Diagnosis of PTLD 3/25 (12) 0/14 (0) 0.54
Cyclophosphamide use 2/25 (8) 2/14 (14.4) 0.85
Tacrolimus use 21/25 (84) 9/14 (64.3) 0.84
Mycophenolate mofetil use 24/25 (96) 13/14 (92.8) 1.00
lymphoproliferative disorder (PTLD) occurred in 3 of the
pediatric patients and in none of the adult patients.
Plasmapheresis was used for the treatment of recurrent
FSGS in 38 of the 39 patients with only one patient not
receiving plasmapheresis. In 9 patients, plasmapheresis was
initiated before transplant and continued after transplanta-
tion.
All patients received rituximab ranging from 1 to 6
doses (median 4). The time from transplant to rituximab
administration was median 210 days (range 4–3543 days).
However, the “gap time” or the number of days from
diagnosis of recurrence of FSGS to rituximab administration
was shorter at median 149 days (range 3–1086 days). In most
cases,rituximabwasusedasalateeﬀorttoachieveremission,
which explains the prolonged gap time.
By univariate analysis for 2 outcomes (no response to
therapy versus any response to therapy), a fewer number
of rituximab infusions (P = 0.007) was associated with a
higher frequency of response (Table 2). This suggests that
patients who responded after the initial rituximab doses
did not receive subsequent infusions. Also, a normal serum
albumin level at the time of FSGS recurrence (P = 0.02)
was associated with any response to rituximab therapy.
The patients who improved with therapy were younger at
the time of transplant (16 versus 30 years), but this was not
statistically signiﬁcant (P = 0.09).
T h ed a t aw e r et h e na n a l y z e df o r3o u t c o m e s( Table 3):
no response, partial remission, and complete remission of
the FSGS recurrence. Male gender was associated with a
higher frequency of achieving remission (P = 0.01). A fewer
number of rituximab infusions was again associated with
response to therapy (P = 0.03). Furthermore, a shorter
time to rituximab treatment following relapse (shorter “gap
time”) was also signiﬁcantly associated with response to
therapy (P = 0.03). A normal serum albumin level at relapse
was also associated with response to therapy (P = 0.05).
The age at diagnosis, recipient age at transplant, time to
ESRD, time from transplant to relapse, transplant source,
degree of proteinuria, number of plasmapheresis sessions,
pretransplant plasmapheresis, immunosuppression used,
and the presence of PTLD were not signiﬁcantly associated
with FSGS remission after rituximab administration. Age at
transplant showed a borderline signiﬁcance of P = 0.07 in a
3-outcome univariate model.
We then ﬁtted two stepwise backward logistic regression
multivariate models, one each for the 2-outcome or 3-
outcome models. We included those variables with complete
data and a P value <0.10 in univariate analyses into the
logistic regression models (number of rituximab doses,
serum albumin at recurrence, age at transplant, male gender,
and time from recurrence to rituximab). The models for
the outcome of any response to therapy revealed that two
variables were signiﬁcantly associated with response after rit-
uximab therapy. A normal serum albumin level at diagnosis
of FSGS recurrence (point estimate 6.46, 95% CI 1.55–26.84,
P value = 0.01) and lower age at transplant (point estimate
0.92,95%CI0.85–0.98,P value = 0.014)werethesigniﬁcant
predictors. In the models for the 3 outcomes, the only two
variables that again predicted a complete response or partial
response over no response to therapy were a normal serum
albumin level at FSGS recurrence (point estimate 4.82, 95%
CI1.54–15.02,P value = 0.007)andalowerageattransplant4 Journal of Transplantation
Table 3: Univariate analysis for the 3-outcome model of complete, partial response, and no response, to rituximab therapy. Values expressed
as median (range) or proportion (%).
Variable Complete response
(n = 17)
Partial response
(n = 8)
No response
(n = 14)
P value
Age at diagnosis (years) 5 (1–33) 7.5 (2–30) 12 (1.9–40) 0.12
Age at transplant (years) 13 (5–48) 22.5 (8–41) 30 (5.5–48) 0.07
Male gender 14/17 (82.4) 2/8 (25) 6/14 (42.8) 0.01
Time to end stage renal disease (years) 3 (0.16–19) 3 (0.6–9) 4 (0.5–12) 0.65
Time to relapse (days) 1 (1–3513) 8 (1–150) 22 (1–828) 0.12
Deceased donor source 11/17 (64.7) 6/8 (75) 10/14 (71.4) 1.00
Serum albumin at relapse (g/dL) 2.7 (1.4–4.4) 3.2 (2–4) 2.3 (1.2–3.3) 0.05
Proteinuria (g/day) 10.25 (1.1–97.4) 5.8 (2–14) 7.64 (2.4–20) 0.19
Plasmapheresis 0.43
<20 treatments 7/17 (41.2) 2/8 (25) 6/14 (42.8)
21–50 treatments 7/17 (41.2) 3/8 (37.5) 2/14 (14.4)
>50 treatments 3/17 (17.6) 3/8 (37.5) 6/14 (42.8)
Pretransplant plasmapheresis 6/17 (35.3) 1/8 (12.5) 2/14 (14.4) 0.37
Posttransplant plasmapheresis 16/17 (94.1) 8/8 (100) 14/14 (100) 1.00
Rituximab doses 2 (2–6) 3 (1–5) 4 (2–6) 0.03
Time from transplant to rituximab (days) 120 (4–3543) 343 (10–1095) 276 (65–1050) 0.08
Time from relapse to rituximab (days) 62 (3–927) 271 (9–1086) 179 (57–1048) 0.03
Diagnosis of PTLD 2/17 (11.8) 1/8 (12.5) 0/14 (0) 0.41
Cyclophosphamide use 1/17 (5.9) 1/8 (12.5) 2/14 (14.4) 0.81
Tacrolimus use 13/17 (76.5) 8/8 (100) 9/14 (64.3) 0.18
Mycophenolate mofetil use 16/17 (94.1) 8/8 (100) 13/14 (92.8) 1.00
(point estimate 0.89, 95% CI 0.82–0.96, P value = 0.003).
Noneoftheothervariablesanalyzedforthe2-or3-outcomes
models were found to be signiﬁcant.
Rituximab infusions were overall well tolerated. Only
twoinvestigatorsreportedsideeﬀectsattributedtorituximab
administration in the posttransplant FSGS patients [20, 23].
One patient developed neutropenia thought to be due to
rituximab and one other a severe anaphylactic reaction at
the time of infusion. Another patient developed BK virus
nephropathy 2 weeks after the third rituximab infusion
and catheter-related severe sepsis two months after the last
rituximab dose [15]. However, the patient had also received
intravenous corticosteroids and a polyclonal antilymphocyte
globulin for treatment of an acute rejection.
4. Discussion
The pathogenesis of primary FSGS is still unclear, and its
recurrence after renal transplant remains a predicament.
Proposed mechanisms include abnormalities in the immune
system including T-cell dysfunction/dysregulation, abnor-
mal cross-talk between T and B cells, cytokines, and an
unidentiﬁed circulating glomerular permeability factor [28].
Recently, Wei et al. have identiﬁed serum soluble urokinase
receptor (suPAR) as a circulating factor that may cause
recurrent FSGS [29]. As a result, intensive therapies like
plasmapheresis in combination with oral cyclophosphamide
or high-dose cyclosporine are commonly prescribed but are
not always successful and accelerated allograft failure ensues.
Rituximab, a chimeric monoclonal antibody against
CD20, was initially approved for the treatment of B-cell
Non-Hodgkin lymphoma and is now used for the treatment
of other hematological malignancies and autoimmune dis-
orders. There have been multiple reports of patients with
steroid-dependent and steroid-resistant nephrotic syndrome
as well as posttransplant FSGS who have been treated with
rituximab (for review see [30]).
Overall, our data show that the response to rituximab
is variable and less eﬀective in posttransplant FSGS as
compared to idiopathic nephrotic syndrome in the native
kidney, where response rates are higher [30]. This ﬁnding
could be explained by the fact that a large proportion of
steroid-dependent and some of the steroid-resistant patients
in the above studies had renal histology consistent with
minimal change disease and not FSGS. The ﬁrst prospective
studyevaluatingrituximabinidiopathicnephroticsyndrome
was performed by Guigonis et al. [31]. The study included
22 patients, 3 with histologic changes of FSGS. Two of the
patients were treated with rituximab after remission had
been achieved and one during relapse. The patient that was
actively nephrotic failed to respond to therapy. Two other
patients, actively nephrotic, did not beneﬁt from rituximab.
The investigators concluded that disease activity may impact
the eﬃcacy of rituximab. By deﬁnition, in posttransplantJournal of Transplantation 5
FSGS, all patients have active disease and heavy proteinuria
which may explain why response to rituximab is lower than
in primary FSGS. In addition, the study by Guigonis also
notedthatrituximabwasmoreeﬀectiveinpatientsonacom-
bination of corticosteroids and a calcineurin inhibitor [31].
However, our analysis revealed that the type of immunosup-
pressive agent was not predictive of response to therapy.
The short-term eﬀects of rituximab in children with
steroid-dependent nephrotic syndrome were evaluated by
Ravani and colleagues in an open-label randomized con-
trolled trial [32]. This study included mostly patients with
renal histology consistent with minimal change disease,
but 25% of patients in the intervention arm that received
rituximab had a diagnosis of FSGS. At 3 months followup,
children who received rituximab had less proteinuria, were
receiving lower prednisone and calcineurin inhibitor doses,
andhadlowerriskofrelapse.However,patientswithsteroid-
resistant or with steroid-dependent nephrotic syndrome
on high-prednisone doses were excluded from this study.
Furthermore,theoutcomeswerenotanalyzedbasedonrenal
histology making it even more diﬃcult to extrapolate the
data to the posttransplant FSGS patient population.
In our present analysis, we did ﬁnd that patients with
a normal serum albumin at the time of recurrent FSGS
diagnosis were more likely to achieve remission. The normal
serum albumin level was documented prior to initiating
plasmapheresis with albumin replacement. There are several
possible reasons for this association. A normal serum
albumin level may imply an earlier stage of disease, when
rituximabmayhaveabetterchanceofworking.Alternatively,
it may imply a milder disease phenotype. It is important to
mention that patients with FSGS secondary to an underlying
immune defect and patients with FSGS due to mutations in
podocyte proteins may have diﬀerent response to therapy.
Furthermore, there have been an increasing number of
podocyte-expressed genes associated with steroid-resistant
nephrotic syndrome in both children and adults. In the
current cohort, NPHS2 mutation analysis was performed
and found to be negative in only 4 patients. Analyses for
other slit-diaphragm-associated proteins were not carried
out in these or any other of the reported patients. Hence,
it is possible that some of the patients may have carried an
unidentiﬁed podocyte protein mutation.
In the initial reports by Nozu and Pescovitz, rituximab
induced complete remission of nephrotic syndrome in a
patient with PTLD and another who developed Epstein-
Barr-virus-driven diﬀuse large cell lymphoma. Follow-up
investigators reported treatment failure with rituximab in
patients without PTLD. In the existing reports, there are only
3 patients treated for malignancy with rituximab. Complete
remission of proteinuria was induced in two and partial
remission in one of the patients. We found no association
between the presence of PTLD and response to rituximab
therapy.
So, how could rituximab be eﬀective in some cases of
recurrent FSGS? It could be assumed that CD20+ cells play
some role in the pathogenesis of posttransplant FSGS. For
instance, Dantal et al. treated four patients with relapse of
focal glomerulosclerosis after transplantation using an (non-
protein A) anti-Ig aﬃnity column and a protein A column
[7]. The two procedures were eﬀective in depleting the
relapsingpatients’plasmaofthefactorcapableofalteringthe
albumin permselectivity of isolated glomeruli in vitro. The
investigators concluded that immunoglobulins have a role
in the recurrence of nephrotic syndrome and suggested that
the responsible factor may be bound to an immunoglobulin.
Furthermore, CD20 is expressed in a fraction of T cells
and this population could be targeted with rituximab as
well with a resulting alteration in T-cell and B-cell cross-
talk [33]. Rituximab can also inhibit nuclear factor kappa
B( N F - κB) pathway in CD20+ cells [34]. NF-κB regulates
cytokine expression which was reported by Sahali et al. to be
altered in patients with nephrotic syndrome. A recent study
suggests that rituximab may act through a B-lymphocyte-
independent mechanism by directly regulating podocyte
activation [35]. Investigators found that rituximab binds
to sphingomyelin phosphodiesterase acid-like 3b (SMPDL-
3b) in podocyte lipid rafts and prevents its downregulation
when exposed to sera from patients with recurrent FSGS.
Rituximab also preserved acid sphingomyelinase enzymatic
activity at normal levels, essential for the organization
of receptors and signaling molecules in the podocyte.
Furthermore, rituximab appears to prevent podocyte actin
remodeling through stabilization of SMPDL-3b.
In summary, multiple immunological mechanisms or
even a direct podocyte eﬀect could be involved in the
response following rituximab administration in some
patients. Overall, complete remission of the proteinuria was
achieved in 17/39 (43.5%) of patients reported to date and
this may be an overestimation. The eﬃcacy of rituximab
in recurrence of FSGS cannot be estimated based on the
current published reports due to possible publication bias, as
patients without response may not have been reported in the
literature and due to the lack of controlled prospective trials.
Also, remission of proteinuria was induced in some patients
several months after rituximab administration, while they
were still receiving other interventions.
In summary, adjuvant therapy with rituximab for recur-
rence of FSGS may be beneﬁcial in only some patients and
the response will likely be evident after the initial medication
doses. A younger age at transplant and a normal serum
albumin level at the time of recurrence seem to predict
response to treatment. Clearly, prospective controlled trials
are needed to prove eﬃcacy and safety of rituximab in
posttransplant FSGS.
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